You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 15, 2025

Suppliers and packagers for VASOPRESSIN IN SODIUM CHLORIDE 0.9%


✉ Email this page to a colleague

« Back to Dashboard


VASOPRESSIN IN SODIUM CHLORIDE 0.9%

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Baxter Hlthcare Corp VASOPRESSIN IN SODIUM CHLORIDE 0.9% vasopressin SOLUTION;INTRAVENOUS 217569 NDA Baxter Healthcare Corporation 0338-9640-12 12 BAG in 1 CARTON (0338-9640-12) / 100 mL in 1 BAG 2023-09-29
Baxter Hlthcare Corp VASOPRESSIN IN SODIUM CHLORIDE 0.9% vasopressin SOLUTION;INTRAVENOUS 217569 NDA Baxter Healthcare Corporation 0338-9647-12 12 BAG in 1 CARTON (0338-9647-12) / 100 mL in 1 BAG 2023-09-29
Long Grove Pharms VASOPRESSIN IN SODIUM CHLORIDE 0.9% vasopressin SOLUTION;INTRAVENOUS 217766 NDA Long Grove Pharmaceuticals, LLC 81298-8552-3 10 VIAL, SINGLE-DOSE in 1 CARTON (81298-8552-3) / 100 mL in 1 VIAL, SINGLE-DOSE (81298-8552-1) 2024-07-12
Long Grove Pharms VASOPRESSIN IN SODIUM CHLORIDE 0.9% vasopressin SOLUTION;INTRAVENOUS 217766 NDA Long Grove Pharmaceuticals, LLC 81298-8554-3 10 VIAL, SINGLE-DOSE in 1 CARTON (81298-8554-3) / 100 mL in 1 VIAL, SINGLE-DOSE (81298-8554-1) 2024-07-12
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: Vasopressin in Sodium Chloride 0.9%

Last updated: July 30, 2025

Introduction

Vasopressin in sodium chloride (NaCl) 0.9%, commonly known as isotonic saline, represents a critical therapeutic agent primarily used for rapidly increasing blood pressure in cases of vasodilatory shock, severe hypotension, and certain forms of diabetes insipidus. As a synthetic analog of the endogenous hormone vasopressin, it plays a vital role in critical care medicine, necessitating a reliable supply chain through reputable manufacturers and distributers.

This article delineates the leading suppliers of vasopressin in sodium chloride 0.9%, exploring their market presence, regulatory compliance, and strategic positioning within the pharmaceutical landscape. It aims to assist healthcare providers, procurement specialists, and industry stakeholders in sourcing high-quality, reliable vasopressin formulations.


Global Market Overview and Manufacturing Landscape

The production of vasopressin formulations is influenced by stringent regulatory standards, including approvals from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other global health authorities. Manufacturers operate under Good Manufacturing Practices (GMP) to ensure product safety, efficacy, and consistency.

Given its role in emergency and intensive care settings, the demand for vasopressin is steady yet specialized, primarily supplied by large multinational pharmaceutical companies with established sterile manufacturing capabilities. The supply chains are highly regulated, with import/export controls impacting availability and pricing.


Major Suppliers of Vasopressin in Sodium Chloride 0.9%

1. Ferring Pharmaceuticals

Overview:
Ferring Pharmaceuticals is among the leading global producers of vasopressin formulations. Their product, Vasopressin (Pitressin), is extensively used in critical care and hospital settings worldwide.

Market Presence and Regulatory Standing:
Ferring maintains a robust regulatory portfolio, with approvals in major markets including the U.S., Europe, and Asia. Their manufacturing facilities adhere to GMP standards, ensuring high-quality sterile formulations.

Product Features:

  • Vasopressin Solution in 0.9% NaCl: Available in various vial sizes for hospital infusion use.
  • Shelf Life: Typically around 24-36 months under proper storage.

Strategic Positioning:
Ferring's emphasis on research and development, coupled with extensive distribution channels, secures their position as a trustworthy source for vasopressin.


2. Sandoz (Novartis Group)

Overview:
Sandoz, a division of Novartis, specializes in biosimilars and sterile injectables, including vasopressin solutions.

Market Presence and Regulatory Status:
They have a significant presence globally, with approvals aligned with FDA and EMA standards. Their manufacturing processes follow strict GMP guidelines, ensuring product integrity for hospital and critical care use.

Product Features:

  • Sandoz offers vasopressin in sterile solution forms suitable for infusion therapy, often supplied in multi-dose vials.

Additional Notes:
Sandoz's extensive international distribution and competitive pricing make it a prominent supplier in both developed and emerging markets.


3. Hikma Pharmaceuticals

Overview:
Hikma specializes in injectable medicines, with vasopressin among their portfolio of hospital-centered injectable drugs.

Market Presence and Regulatory Status:
Operates manufacturing plants approved by regulatory agencies; their vasopressin products are available in multiple regions, including the Middle East, Europe, and the Americas.

Product Features:

  • Sterile vasopressin solutions in sodium chloride 0.9%.
  • Emphasis on stability and compatibility for infusion systems.

Strategic Focus:
Hikma's focus on accessible formulations and regional manufacturing capacity positions them as a reliable supplier for hospitals seeking cost-effective options.


4. Merck KGaA (EMD Serono in the US)

Overview:
Merck KGaA's EMD Serono division produces vasopressin formulations used in critical care settings.

Regulatory and Market Reach:
Their vasopressin products are approved in Europe and the United States with a focus on quality assurance and clinical efficacy.

Product Details:

  • Available as sterile solutions suitable for infusion.
  • Conforms to international pharmacopoeia standards.

Strategic Offerings:
Their integration into global supply chains assures consistent product availability.


5. Pfizer Inc.

Overview:
Pfizer is a prominent manufacturer of various injectable therapies, including vasopressin analogs and formulations.

Market Position:
Their products are widely distributed, with supply agreements aligned with hospital procurement systems.

Product Features:

  • Vasopressin solutions in sterile sodium chloride 0.9% formulations.
  • Focus on stability, sterility, and ease of administration.

Regulatory Compliance:
Certified under GMP, ensuring adherence to international standards.


Additional Notable Suppliers and Distributors

  • Baxter International: Known for their critical care and infusion products, including vasopressin formulations.
  • ICU Medical: Supplies vasopressin solutions used in intensive unit settings.
  • Hospira (a Pfizer company): Provides hospital-grade vasopressin formulations and infusion solutions.

Supply Chain and Procurement Considerations

Healthcare institutions and procurement agencies must evaluate suppliers based on several factors, including:

  • Regulatory Approvals: Ensure products meet regional and international standards (FDA, EMA, WHO GMP).
  • Product Packaging and Stability: Verify vial sizes, expiration dates, and storage conditions.
  • Price and Reimbursement: Consider negotiated contract pricing, especially for bulk procurement.
  • Supply Reliability: Confirm distributor capacity to meet urgent and ongoing needs.
  • Traceability and Pharmacovigilance: Ensure supplier compliance with adverse event reporting.

Given the critical nature of vasopressin therapy, establishing partnerships with multiple approved suppliers mitigates supply risks and ensures continuity of care.


Key Takeaways

  • Leading global suppliers include Ferring Pharmaceuticals, Sandoz (Novartis), Hikma Pharmaceuticals, Merck KGaA, and Pfizer.
  • All suppliers adhere to stringent GMP standards, ensuring product quality and safety.
  • Availability varies by region; thus, local regulatory approvals influence supplier choices.
  • Supply chain robustness is critical; diversifying suppliers minimizes shortages.
  • Procurement should prioritize regulatory compliance, product stability, and reliable distribution channels.

FAQs

1. What factors should I consider when sourcing vasopressin in sodium chloride 0.9%?
Focus on regulatory approval, GMP compliance, product stability, packaging, supplier reputation, and logistical reliability.

2. Are biosimilar vasopressin products available?
Yes, companies like Sandoz offer biosimilar vasopressin formulations that can meet same efficacy and safety standards as originator products.

3. How do regulatory differences impact vasopressin supply?
Regulatory approvals influence market access. Some suppliers may have approvals only in specific regions, affecting procurement options.

4. Can I procure vasopressin from local distributors?
Yes, but verify their supply chain integrity, regulatory compliance, and product authenticity before purchase.

5. Is there a significant price difference among suppliers for vasopressin in sodium chloride 0.9%?
Pricing varies based on regional market conditions, supplier contracts, and quantity, making negotiations crucial for procurement.


References

  1. Ferring Pharmaceuticals. Product information and commercial details.
  2. Sandoz. Vasopressin formulations and EMA approval data.
  3. Hikma Pharmaceuticals. Product specifications for injectable vasopressin.
  4. EMA and FDA regulatory documentation. Standards and approval status.
  5. Global healthcare procurement reports. Market analysis and supplier evaluations.

This comprehensive guide aims to empower healthcare professionals and procurement specialists with actionable insights into sourcing vasopressin in sodium chloride 0.9%, ensuring reliable access to this critical emergency medication.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.